GLP-1 as a target for therapeutic intervention

Current Opinion in Pharmacology

Volumn 31, Issue , 2016, Pages 44-49

  Rajeev, Surya Panicker ^a   Wilding, John ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LIRAGLUTIDE; LIXISENATIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; INSULIN;

ANTIDIABETIC ACTIVITY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENERGY EXPENDITURE; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; INCIDENCE; NAUSEA; OBESITY; PANCREATITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VOMITING; WEIGHT REDUCTION; AGONISTS; BODY WEIGHT; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; OBESITY;

EID: 84984677355     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.08.005     Document Type: Review

References (57)

1. 1 Elrick, H., Stimmler, L., Hlad, C.J. Jr., Arai, Y., Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24 (1964), 1076–1082.
2. 2 Bell, G.I., Sanchez-Pescador, R., Laybourn, P.J., Najarian, R.C., Exon duplication and divergence in the human preproglucagon gene. Nature 304 (1983), 368–371.
3. 3 Bagger, J.I., Knop, F.K., Lund, A., Vestergaard, H., Holst, J.J., Vilsboll, T., Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 96 (2011), 737–745.
4. 4 Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17 (2013), 819–837.
5. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44 (1995), 1126–1131.
6. 2+ channel-dependent exocytosis. Cell Metab 11 (2010), 543–553.
7. 7 Hare, K.J., Vilsboll, T., Asmar, M., Deacon, C.F., Knop, F.K., Holst, J.J., The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59 (2010), 1765–1770.
8. 8 Nauck, M.A., Niedereichholz, U., Ettler, R., Holst, J.J., Orskov, C., Ritzel, R., Schmiegel, W.H., Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273 (1997), E981–E988.
9. 9 Meier, J.J., Gethmann, A., Gotze, O., Gallwitz, B., Holst, J.J., Schmidt, W.E., Nauck, M.A., Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49 (2006), 452–458.
10. 10 Eng, J., Kleinman, W.A., Singh, L., Singh, G., Raufman, J.P., Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267 (1992), 7402–7405.
11. 11 Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S., Baron, A.D., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004), 2628–2635.
12. 12 Derosa, G., Maffioli, P., Salvadeo, S.A., Ferrari, I., Ragonesi, P.D., Querci, F., Franzetti, I.G., Gadaleta, G., Ciccarelli, L., Piccinni, M.N., D'Angelo, A., Cicero, A.F., Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 12 (2010), 233–240.
13. 13• Diamant, M., Nauck, M.A., Shaginian, R., Malone, J.K., Cleall, S., Reaney, M., de Vries, D., Hoogwerf, B.J., MacConell, L., Wolffenbuttel, B.H., Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37 (2014), 2763–2773 This was a 30-week, open-label, multicenter, randomized, non-inferiority trial on 627 patients comparing exenatide twice daily with meal time insulin lispro in patients achieving inadequate glycaemic control on basal insulin and metformin. Exenatide resulted in similar glycaemic control compared with insulin lispro, was well tolerated and resulted in weight reduction.
14. 14 Zinman, B., Hoogwerf, B.J., Duran Garcia, S., Milton, D.R., Giaconia, J.M., Kim, D.D., Trautmann, M.E., Brodows, R.G., The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146 (2007), 477–485.
15. 15 Drucker, D.J., Buse, J.B., Taylor, K., Kendall, D.M., Trautmann, M., Zhuang, D., Porter, L., Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372 (2008), 1240–1250.
16. 16 Buse, J.B., Rosenstock, J., Sesti, G., Schmidt, W.E., Montanya, E., Brett, J.H., Zychma, M., Blonde, L., Group, L.-S., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 (2009), 39–47.
17. 17 Riddle, M.C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., Rosenstock, J., Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 36 (2013), 2489–2496.
18. 18 Riddle, M.C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., Rosenstock, J., Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 36 (2013), 2497–2503.
19. 19 Yu Pan, C., Han, P., Liu, X., Yan, S., Feng, P., Zhou, Z., Lv, X., Tian, H., Jin Kui, Y., Su, B., Shang, S., Niemoeller, E., Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev 30 (2014), 726–735.
20. 20 Rosenstock, J., Hanefeld, M., Shamanna, P., Min, K.W., Boka, G., Miossec, P., Zhou, T., Muehlen-Bartmer, I., Ratner, R.E., Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complicat 28 (2014), 386–392.
21. 21 Rosenstock, J., Raccah, D., Koranyi, L., Maffei, L., Boka, G., Miossec, P., Gerich, J.E., Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 36 (2013), 2945–2951.
22. 22 Werner, U., Haschke, G., Herling, A.W., Kramer, W., Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 164 (2010), 58–64.
23. 23 Bergenstal, R.M., Wysham, C., Macconell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., Porter, L.E., Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376 (2010), 431–439.
24. 24 Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., Trautmann, M., Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375 (2010), 2234–2243.
25. 25 Russell-Jones, D., Cuddihy, R.M., Hanefeld, M., Kumar, A., Gonzalez, J.G., Chan, M., Wolka, A.M., Boardman, M.K., Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35 (2012), 252–258.
26. 26 Marre, M., Shaw, J., Brandle, M., Bebakar, W.M., Kamaruddin, N.A., Strand, J., Zdravkovic, M., Le Thi, T.D., Colagiuri, S., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Med 26 (2009), 268–278.
27. 27 Nauck, M., Frid, A., Hermansen, K., Shah, N.S., Tankova, T., Mitha, I.H., Zdravkovic, M., During, M., Matthews, D.R., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32 (2009), 84–90.
28. 28 Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P.A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P.M., Zdravkovic, M., Bode, B., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009), 473–481.
29. 29 Zinman, B., Gerich, J., Buse, J.B., Lewin, A., Schwartz, S., Raskin, P., Hale, P.M., Zdravkovic, M., Blonde, L., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32 (2009), 1224–1230.
30. 30 Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B.K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G.M., Simo, R., Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52 (2009), 2046–2055.
31. 31 Degn, K.B., Juhl, C.B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B.R., Schmitz, O., One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53 (2004), 1187–1194.
32. 32 Buse, J.B., Nauck, M., Forst, T., Sheu, W.H., Shenouda, S.K., Heilmann, C.R., Hoogwerf, B.J., Gao, A., Boardman, M.K., Fineman, M., Porter, L., Schernthaner, G., Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381 (2013), 117–124.
33. 33 Buse, J.B., Garber, A., Rosenstock, J., Schmidt, W.E., Brett, J.H., Videbaek, N., Holst, J., Nauck, M., Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 96 (2011), 1695–1702.
34. 34 Reusch, J., Stewart, M.W., Perkins, C.M., Cirkel, D.T., Ye, J., Perry, C.R., Reinhardt, R.R., Bode, B.W., Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab 16 (2014), 1257–1264.
35. 35 Nauck, M.A., Stewart, M.W., Perkins, C., Jones-Leone, A., Yang, F., Perry, C., Reinhardt, R.R., Rendell, M., Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia 59 (2016), 266–274.
36. 36 Weissman, P.N., Carr, M.C., Ye, J., Cirkel, D.T., Stewart, M., Perry, C., Pratley, R., HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia 57 (2014), 2475–2484.
37. 37 Home, P.D., Shamanna, P., Stewart, M., Yang, F., Miller, M., Perry, C., Carr, M.C., Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab 17 (2015), 179–187.
38. 38 Pratley, R.E., Nauck, M.A., Barnett, A.H., Feinglos, M.N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., Rosenstock, J., Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2 (2014), 289–297.
39. 39 Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32 (2009), 1880–1886.
40. 40 Weinstock, R.S., Guerci, B., Umpierrez, G., Nauck, M.A., Skrivanek, Z., Milicevic, Z., Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab 17 (2015), 849–858.
41. 41 Umpierrez, G., Tofe Povedano, S., Perez Manghi, F., Shurzinske, L., Pechtner, V., Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 37 (2014), 2168–2176.
42. 42 Giorgino, F., Benroubi, M., Sun, J.H., Zimmermann, A.G., Pechtner, V., Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 38 (2015), 2241–2249.
43. 43 Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., Lakshmanan, M., Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 37 (2014), 2159–2167.
44. 44 Dungan, K.M., Povedano, S.T., Forst, T., Gonzalez, J.G., Atisso, C., Sealls, W., Fahrbach, J.L., Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384 (2014), 1349–1357.
45. 45 Buteau, J., Foisy, S., Joly, E., Prentki, M., Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52 (2003), 124–132.
46. 46 Bunck, M.C., Corner, A., Eliasson, B., Heine, R.J., Shaginian, R.M., Taskinen, M.R., Smith, U., Yki-Jarvinen, H., Diamant, M., Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34 (2011), 2041–2047.
47. 47 Buse, J.B., Vilsboll, T., Thurman, J., Blevins, T.C., Langbakke, I.H., Bottcher, S.G., Rodbard, H.W., Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 37 (2014), 2926–2933.
48. 48 Day, J.W., Ottaway, N., Patterson, J.T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D.J., Chaudhary, N., Holland, J., Hembree, J., Abplanalp, W., Grant, E., Ruehl, J., Wilson, H., Kirchner, H., Lockie, S.H., Hofmann, S., Woods, S.C., Nogueiras, R., Pfluger, P.T., Perez-Tilve, D., DiMarchi, R., Tschop, M.H., A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5 (2009), 749–757.
49. 49 Cegla, J., Troke, R.C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K.A., Lim, C.T., Parvizi, N., Hussein, M., Chambers, E.S., Minnion, J., Cuenco, J., Ghatei, M.A., Meeran, K., Tan, T.M., Bloom, S.R., Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63 (2014), 3711–3720.
50. 50• Egan, A.G., Blind, E., Dunder, K., de Graeff, P.A., Hummer, B.T., Bourcier, T., Rosebraugh, C., Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N Engl J Med 370 (2014), 794–797 Causality of pancreatitis and pancreatic cancer with incretin based therapy are inconsistent with available data.
51. 51 Bjerre Knudsen, L., Madsen, L.W., Andersen, S., Almholt, K., de Boer, A.S., Drucker, D.J., Gotfredsen, C., Egerod, F.L., Hegelund, A.C., Jacobsen, H., Jacobsen, S.D., Moses, A.C., Molck, A.M., Nielsen, H.S., Nowak, J., Solberg, H., Thi, T.D., Zdravkovic, M., Moerch, U., Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151 (2010), 1473–1486.
52. 52 Hegedus, L., Moses, A.C., Zdravkovic, M., Le Thi, T., Daniels, G.H., GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 96 (2011), 853–860.
53. 53 Chilton, R., Wyatt, J., Nandish, S., Oliveros, R., Lujan, M., Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagon like peptide-1-based therapies. Am J Med 124 (2011), S35–S53.
54. 54•• Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., Lawson, F.C., Ping, L., Wei, X., Lewis, E.F., Maggioni, A.P., McMurray, J.J., Probstfield, J.L., Riddle, M.C., Solomon, S.D., Tardif, J.C., Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257 This was a cardiovascular outcome trial designed to demonstrate non-inferiority as well as superiority of lixisenatide in patients with type 2 diabetes and a recent history of an acute coronary event. The trial in 6068 patients followed-up for a median duration of 25 months concluded that lixisenatide added to standard care did not alter the rate of major cardiovascular events or serious adverse events.
55. 55•• Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., Nissen, S.E., Pocock, S., Poulter, N.R., Ravn, L.S., Steinberg, W.M., Stockner, M., Zinman, B., Bergenstal, R.M., Buse, J.B., Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2016 The LEADER trial was a multicenter, randomised, placebo-controlled cardiovascular outcome trial in 9340 patients with high cardiovascular risk; median follow-up was 3.8 years. It was designed to demonstrate non-inferiority of liraglutide, but it demonstrated superiority with lower rates of cardiovascular events and deaths from any cause in the liraglutide group compared to placebo.
56. 56• Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D.C., le Roux, C.W., Violante Ortiz, R., Jensen, C.B., Wilding, J.P., A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373 (2015), 11–22 This was a 56-week, double-blind trial in 3731 patients without type 2 diabetes and BMI >30 or BMI >27 with hypertension or dyslipidemia randomised to 3 mg liraglutide or placebo. The study demonstrated that liraglutide resulted in reduced body weight and improved metabolic risk factors compared with placebo.
57. 57 Davies, M.J., Bergenstal, R., Bode, B., Kushner, R.F., Lewin, A., Skjoth, T.V., Andreasen, A.H., Jensen, C.B., DeFronzo, R.A., Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. J Am Med Assoc 314 (2015), 687–699.